AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Jun 26, 2017
35334_dirs_2017-06-26_6e0f4af6-bcde-4be6-b6b6-f1c352fafc26.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-04-30
Reporting Person: MITCHELL WILLIAM M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-04-30 | Options to buy Common Stock | $0.67 | A | 12644 | Acquired | 2027-04-30 | Common Stock (12644) | Direct |
| 2017-05-15 | Options to buy Common Stock | $0.64 | A | 13238 | Acquired | 2027-05-15 | Common Stock (13238) | Direct |
| 2017-05-31 | Options to buy Common Stock | $0.59 | A | 14361 | Acquired | 2027-05-31 | Common Stock (14361) | Direct |
| 2017-06-15 | Options to buy Common Stock | $0.49 | A | 17287 | Acquired | 2027-06-15 | Common Stock (17287) | Direct |
Footnotes
F1: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees.